Antennova to Present ATN-037 Data at ESMO Congress 2024

Antennova, a Boston-based clinical-stage biotech firm specializing in oncology, has announced that it will showcase the latest findings on its CD73 small molecule inhibitor, ATN-037, at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2024). The event will take place from September 13th to September 17th at the Fira Barcelona Gran Via in Barcelona, Spain.

The presentation, titled "A First-In-Human Phase I/Ib study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Advanced Solid Tumors – STAMINA-01," will occur on September 16, 2024. The time slots are 10:50 AM – 10:55 AM Central European Summer Time and 4:50 AM – 4:55 AM US Eastern Time. The abstract for the presentation is numbered 6067, and the presentation number is 997MO.

ATN-037, also referred to as ATG-037, is a highly potent oral small molecule inhibitor targeting CD73. The STAMINA-01 Phase I/II study is designed to evaluate the safety, pharmacokinetics, and optimal dosing of ATN-037, both as a standalone therapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in patients with refractory or relapsed solid tumors. Antennova has initiated the dose optimization and dose expansion phase of the Phase II STAMINA trial in Australia, with plans to extend the study to China by the end of October 2024.

As of February 29, 2024, the study had enrolled 32 patients, with doses ranging from 20mg twice daily (BID) to 600mg BID. Among these, 20 patients with checkpoint inhibitor (CPI) resistance were treated with a combination therapy including KEYTRUDA®. In the monotherapy cohort of 32 evaluable patients, 14 achieved stable disease (SD), resulting in a disease control rate (DCR) of 43.8%. In the combination therapy cohort, comprising 20 patients, 15 were evaluable. Of these, three patients (two with melanoma and one with non-small cell lung cancer (NSCLC)) achieved a confirmed partial response (PR), and one patient with NSCLC had an unconfirmed PR. The overall response rate (ORR) for this group was 20.0%. Additionally, nine patients achieved stable disease (SD), leading to a disease control rate (DCR) of 65.0%.

Regarding safety, 40.6% of patients on monotherapy and 25.0% on combination therapy reported treatment-related adverse events (TRAEs). Notably, only one patient receiving combination therapy experienced a dose-limiting toxicity, specifically a grade 3 rash. All other TRAEs were of lower severity, graded 1-2.

Updated findings as of July 26, 2024, will be presented during the Mini Oral Session of the ESMO Congress 2024 on September 16.

Antennova, a Delaware corporation and a subsidiary of Antengene, is a clinical-stage biotech company that develops innovative therapeutics targeting key biological mechanisms that allow cancers to resist current treatments. Their pipeline includes several oncology candidates aimed at enhancing the efficacy of standard therapies, reversing CPI resistance, and targeting "cold tumors" unresponsive to current CPI therapies. Among their accomplished milestones are four clinical-stage programs: ATN-031 (anti-CD24 monoclonal antibody), ATN-037 (CD73 oral small molecule inhibitor), ATN-022 (Claudin 18.2 ADC), and ATN-101 (anti-PD-L1/4-1BB bispecific antibody). The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to ATN-022 for gastric and pancreatic cancers and to ATN-101 for pancreatic cancer.